Sharpley FA, et al. - Researchers report the experience of the UK National Amyloidosis Centre with pomalidomide as a treatment option for patients with relapsed light chain (AL) amyloidosis. They ultimately intended to determine the real-world outcomes of pomalidomide in this population. They analyzed data on treatment toxicity and clonal response for all patients with AL amyloidosis treated with pomalidomide between 2009 and 2017. Using the Kaplan-Meier method, survival was calculated, and outcomes reported on an intent-to-treat (ITT) basis. Median overall survival and median progression free survival was 27 months and 15 months, respectively. Pomalidomide displayed activity in patients with relapsed AL amyloidosis, and responses were rapid. A sustained overall response could be predicted by early responses. Only a third of all patients exhibited deep responses (very good partial response or better).